Gilead Reports a $320 Million RCUS Buy, Raises Its Stake to 40%

JC Parets
February 1, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes in a series of Form 4 filings by Gilead Sciences.

The American biopharmaceutical company revealed a purchase of roughly $320 million in Arcus Biosciences Inc $RCUS, increasing its ownership stake to 40%.

Director Mark McDade reported a $3,250,000 purchase in Tourmaline Bio Inc $TRML.

Here’s The Hot Corner, with data through January 31, 2024:

In another Form 4, Daniela Mielke, director of The Bancorp Inc $TBBK, revealed a purchase of 3,315 shares.

Stay tuned. We'll be back on Friday with more insider activity.

To have these insider transactions e-mailed to you every morning, sign up for The Hot Corner.

And please reach out with any questions. We love hearing from you!

All Star Charts Team

Filed Under: